29
Participants
Start Date
June 28, 2013
Primary Completion Date
September 15, 2018
Study Completion Date
September 28, 2018
Gemcitabine-Pazopanib
2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital, Athens
Dept of Medical Oncology, 251 General Air Force Hospital, Athens
"2nd Dept of Internal Medicine, General Hospital of Athens Hippokratio", Athens
Oncology Dept, 2nd Surgyc Clinic, Aretaieio Hospital, Athens
"Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens Alexandra", Athens
"Division of Oncology, 2nd Dept of Internal Medicine, Propaedeutic, University Hospital Attikon", Athens
2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital, Athens
3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital, Athens
3rd Dept of Medical Oncology, Hygeia Hospital, Athens
1st Dept of Medical Oncology, Metropolitan Hospital, Athens
2nd Dept of Medical Oncology, Metropolitan Hospital, Athens
Division of Oncology, Dept of Internal Medicine, University Hospital of Patras, Pátrai
Dept of Medical Oncology, Ioannina University Hospital, Ioannina
2nd Dept of Medical Oncology, EUROMEDICA General Clinic of Thessaloniki, Thessaloniki
Dept of Medical Oncology, Papageorgiou General Hospital, Thessaloniki
Dept of Medical Oncology, Thermi Clinic S.A, Thessaloniki
Dept of Medical Oncology, University Hospital of Heraklion, Heraklion
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Hellenic Cooperative Oncology Group
OTHER